EN DE
Watch Unicycive Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Unicycive Therapeutics Inc (UNCY) fair value: what the stock is really worth

As of Nov 12, 2026: fair value (intrinsic value) of Unicycive Therapeutics Inc stock $2.95, price $3.64, that is 19.0% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US90466Y1038

UT Unicycive Therapeutics Inc logo Thin data Nov 13, 2026

Unicycive Therapeutics Inc

UNCY · US

Expensive (fair value 19% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 42/100 
Mixed vs. peers (4/7) 
Fair value $2.95 · Overvalued 
Falling price (downtrend) 
Weak Growth (revenue YoY −29.0 %/yr in USD) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Unicycive Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$30.50 $2.36 Fair Value $2.95 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range $2.36 – $30.50 · fair‑value band $2.21 – $3.69 · the $3.64 price screens above the $2.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Unicycive Therapeutics in your weekly email

Every Wednesday you see whether Unicycive Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.

Show moreShow less

It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

The company was incorporated in 2016 and is headquartered in Mountain View, California.

Stock analysis

Unicycive Therapeutics Inc (UNCY) currently trades at $3.64, while our estimate is $2.95, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.21 (bear) to $3.69 (bull), the price of $3.64 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Unicycive Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$26.6M in FY2025.

Key figures

Market cap $98.0M Micro · EPS (TTM) $−1.72 · Return on equity −101% · Return on assets (EBIT) −199% (5-year average) · Free cash flow −$31.3M · Net cash $29.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −19%, UNCY screens richer than that median.

Fair Value

Bear $2.21 Fair Value $2.95 Bull $3.69
Price $3.64 · Downside -19.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 45
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 12, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

UNCY screens overvalued: fair value 19% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Unicycive Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −19.0% · Above median
Profitability
Return on assets −54.0% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.24× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $951.19 $1,275 +34% vs UNCY
Vertex Pharmaceuticals Incorporated VRTX $542.62 $602.68 +11% vs UNCY
Genmab A/S GMAB kr 3,530 kr 3,917 +11% vs UNCY
Samsung Biologics Co 207940 1,449,000 KRW 1,573,000 KRW +9% vs UNCY
argenx SE ARGX $981.33 $908.40 −7% vs UNCY
CSL Limited CSL A$202.92 A$183.54 −10% vs UNCY
Moderna, Inc MRNA $231.35 $139.99 −39% vs UNCY
BeOne Medicines AG 6160 HK$255.80 HK$152.80 −40% vs UNCY
Celltrion, Inc 068270 209,500 KRW 74,945 KRW −64% vs UNCY
Royalty Pharma plc RPRX $68.97 $19.01 −72% vs UNCY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Unicycive Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Unicycive Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/UNCY

Frequently asked questions

Is Unicycive Therapeutics Inc (UNCY) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is $2.95 versus a price of $3.64, about 19% lower (overvalued).
What is the fair value of UNCY?
Our estimate for Unicycive Therapeutics Inc is $2.95 (as of Nov 13, 2026), built from audited fundamentals. The current price: $3.64.
What is the quality score of UNCY?
Unicycive Therapeutics Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Unicycive Therapeutics Inc (UNCY)?
Our calculated price target is the estimate of $2.95 (as of Nov 13, 2026). Cautious scenario $2.21, optimistic scenario $3.69. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Unicycive Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $2.95, about 19% lower versus a price of $3.64 (overvalued). Cautious scenario $2.21, optimistic scenario $3.69. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Unicycive Therapeutics Inc (UNCY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Unicycive Therapeutics Inc it is $2.95 per share (as of Nov 13, 2026), against a price of $3.64.
Is Unicycive Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 13, 2026, UNCY trades above its calculated fair value: price $3.64, fair value $2.95, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UNCY?
No. The price is what the market pays today ($3.64); the fair value is what the company's own numbers justify ($2.95). For Unicycive Therapeutics Inc the two are $0.6900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Unicycive Therapeutics Inc worth?
The market values Unicycive Therapeutics Inc at about $98.0M (market capitalisation, as of Nov 13, 2026). Per share that is $3.64; our models calculate a fair value of $2.95 per share.
What do the bullish and bearish scenarios say about UNCY?
Our models span a range for Unicycive Therapeutics Inc: cautious scenario $2.21, base $2.95, optimistic $3.69 per share (as of Nov 13, 2026, price $3.64). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Unicycive Therapeutics Inc (UNCY)?
Balance-sheet figures for Unicycive Therapeutics Inc (as of Nov 13, 2026): return on equity −101.1%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is UNCY from its 52-week high?
Unicycive Therapeutics Inc trades at $3.64, about 57% below its 52-week high of $8.56 and 8% above the low of $3.36 (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of $2.95 is for.
Which stocks are comparable to Unicycive Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Unicycive Therapeutics Inc stock attractive at the current price?
The data as of Nov 13, 2026: price $3.64, calculated fair value $2.95 (−19%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Unicycive Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Unicycive Therapeutics Inc (UNCY)?
The closing price on Nov 12, 2026 was $3.64. Our estimate is $2.95, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Unicycive Therapeutics Inc right now?
Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Unicycive Therapeutics Inc

How large is the market capitalisation of Unicycive Therapeutics Inc (UNCY)?
The market capitalisation of Unicycive Therapeutics Inc is $98.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Unicycive Therapeutics Inc (UNCY)?
Earnings per share at Unicycive Therapeutics Inc are $−1.72. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Unicycive Therapeutics Inc (UNCY)?
The return on equity (ROE) of Unicycive Therapeutics Inc is −101% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Unicycive Therapeutics Inc (UNCY)?
On an EBIT basis the return on assets of Unicycive Therapeutics Inc is −199% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Unicycive Therapeutics Inc (UNCY) generate?
The free cash flow of Unicycive Therapeutics Inc is −$31.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Unicycive Therapeutics Inc (UNCY) hold?
Unicycive Therapeutics Inc holds more cash than debt, $29.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Unicycive Therapeutics Inc in the live analysis

One click puts Unicycive Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.